1. As to Plaintiff A’s KRW 14,019,84 won, Plaintiff B, C, D, and E respectively, and each of the said money on April 1, 2014.

1. Basic facts

A. The Defendant is a pharmacist operating the “H pharmacy” on the first floor of the building in Sungnam-si, Sungnam-si, and the Plaintiff is a person who received medicine prepared by the Defendant from the above H pharmacy, and the Plaintiff B, D, and E are the Plaintiff’s parents, Plaintiff C, and Plaintiff A’s children.

B. On March 31, 2014, Plaintiff A issued a prescription to “H pharmacy” located on the 5th floor of the said G building with the term “in 1st century”, and received the said prescription to “IB” located on the 1st floor of the same building.

C. On April 1, 2014, the Defendant delivered medicine to the Plaintiff on the grounds that some of the drugs prescribed above were not a pharmacy, and the Defendant issued, by mistake, the Plaintiff, not the Plaintiff, a drug prepared for J, “self-fibex X-gumincation, glzzzin, glzin, glin, news glin, hurdembin, hurgra.”

(hereinafter “instant accident”). D.

On April 17, 2014, the Plaintiff filed a petition for re-explosion and re-explosion to the emergency room of the Seoul National University Hospital. On April 21, 2014, the Plaintiff was diagnosed as “unexplosion, re-explosion and re-explosion, in detail, and in detail,” and was diagnosed on June 3, 2014.

[Ground of recognition] Facts without dispute, Gap evidence 1 through 5, Eul evidence 1 and 2 (including branch numbers; hereinafter the same shall apply), the purport of the whole pleadings

2. The parties' assertion

A. The plaintiffs asserted that the plaintiff A suffered chronic kidne diseases, injuries to the unknown chronic chymosis, etc., and injuries to both sides due to the accidents in this case caused by the defendant's negligence.

Therefore, pursuant to Article 750 of the Civil Act, the Defendant is damages for the instant accident, and KRW 502,451,279 to the Plaintiff = 5,365,010,705 from the Japanese Pharmaceutical Association (Korean Pharmaceutical Association) for future medical treatment costs of KRW 72,084,810,000.